Aquestive Therapeutics Investor Relations Material
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company develops drugs for serious or life-threatening illnesses with unmet need by utilizing its chemistry expertise of developing enzyme inhibitors. It offers lead product ABT-199, which is a potent inhibitor against two enzymes involved in virus replication; and candidates that are being developed for the treatment of disorders related to protein misfolding. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Key slides for Aquestive Therapeutics Inc
Rubrik's 2024 IPO: What Investors Need To Know
Explore Rubrik's journey to a 2024 IPO, its innovative cybersecurity solutions, and strategic growth, highlighting its impact on the tech sector.
29 Feb 2024
Pricing Power Through Scarcity: A Case Study of Ferrari
Explore how Ferrari's scarcity and brand strength amplify its pricing power, crucial for a luxury company's success.
27 Feb 2024
Jacob Wallenberg: The Chairman of Investor AB
Get to know Jacob Wallenberg, one of the most influential businessmen in Europe and a part of the fifth generation of the Wallenberg family.
28 Feb 2024
🇺🇸 United States